ALFA Finder| Revenue growth | FY26 consolidated ₹142 cr; India business grew 10% YoY. |
|---|---|
| Margins | Standalone EBITDA at 55%; consolidated FY26 EBITDA at 40%. |
| Order book | Coris has €2.4M remaining in HAT contract for Congo. |
| Demand visibility | Visibility from long-term reagent rentals and institutional supply programs. |
| Management confidence | High confidence in US FDA approvals and 15-20% growth guidance. |
Growth
FY26 revenue grew to ₹142 cr; 3B India molecular diagnostics grew 10% YoY to ₹86.47 cr.
Outlook
Targeting 15-20% revenue and EBITDA growth for FY27; US FDA submission for AMR products ongoing; M&A active search.
Risks
Geopolitical tensions in Middle East impacting exports; seasonality in flu/dengue demand; increased competition in low-priced assays.
Earnings Call filed with BSE, NSE: 3BBLACKBIO. Summary written with AI assistance from the document.
3B BlackBio Dx Ltd: key numbers
- Share price
- ₹1,332.80
- Market cap
- ₹1,144 Cr
- Revenue (annual)
- ₹141.9 Cr
- Net profit (annual)
- ₹59.93 Cr
- P/E (TTM)
- 20.6×Sector 35.5×
- Promoter holding
- 40.95%+0.00% QoQ
- FII holding
- 2.46%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from 3B BlackBio Dx Ltd
All →3B BlackBio Dx Board Meeting Date
3B BlackBio Dx Ltd has scheduled a board meeting for November 13, 2026. The board will consider unaudited standalone and consolidated financial results for the quarter ended September 30, 2026.
3B BlackBio Dx Other Announcement
The company submitted its quarterly shareholding pattern as per Regulation 31(1)(b) of the SEBI Listing Regulations for the period ending September 30, 2026.
3B BlackBio Dx Other Announcement
3B BlackBio DX Limited announced the re-appointment of Mrs. Mithla Dubey as a Non-Executive Non-Independent Director. Her re-appointment follows retirement by rotation.
3B BlackBio Dx Annual General Meeting
3B BlackBio Dx Ltd shareholders approved a dividend of Rs. 5.00 per share at its 54th AGM. The company also presented an investor overview of its FY26 performance.
3B BlackBio Dx Other Announcement
3B BlackBio Dx sent a Reg 36(1)(b) letter to shareholders providing the weblink to its FY 2025-26 Annual Report ahead of the 54th AGM. No financial figures or business events are disclosed.
3B BlackBio Dx Annual Report
3B BlackBio Dx Ltd filed its FY 2025-26 Annual Report with BSE under Regulation 34(1). The report recaps its molecular diagnostics growth and global expansion.